135734-96-2

Basic information

• Product Name: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone
• Synonyms: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone
• CAS NO: 135734-96-2
• Molecular Formula: C₁₃H₁₄O₃
• Molecular Weight: 218.24846
• Mol File: 135734-96-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone(CAS DataBase Reference)
• NIST Chemistry Reference: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone(135734-96-2)
• EPA Substance Registry System: (E)-2-(4-hydroxy-3-Methoxybenzylidene)cyclopentanone(135734-96-2)

Safety Data

• Hazardous Substances Data: 135734-96-2(Hazardous Substances Data)

Usage

Uses

Used in the Food Industry:
HMC is used as a flavoring agent for its distinctive odor, enhancing the taste and aroma of various food products.
Used in Pharmaceutical Applications:
HMC is used as a potential candidate for pharmaceutical products due to its antioxidant, anti-inflammatory, and anti-cancer properties. It is being investigated for its potential use in the treatment of neurodegenerative diseases such as Alzheimer's.
Used in Nutraceutical Applications:
HMC is used in the development of nutraceutical products, capitalizing on its health-promoting benefits, including its antioxidant and anti-inflammatory properties.
Used in Antimicrobial and Antifungal Applications:
HMC is being studied for its potential antimicrobial and antifungal properties, which could lead to its use in the development of new drug therapies to combat infections.
Used in Drug Development:
HMC is investigated for its potential use in the development of new drug therapies, particularly in the treatment of cancer and neurodegenerative diseases, due to its multifaceted biological activities.

Upstream product

• 936-52-7 1-(N-morpholino)cyclopent-1-ene 
• 121-33-5 vanillin 
• 13330-65-9 2,4-dimethoxyphenol 
• 120-92-3 cyclopentanone 

Downstream Products

• 1393829-61-2 2-(4-hydroxy-3-methoxybenzylidene)-5-(4-hydroxybenzylidene)cyclopentanone 

Relevant articles and documents

Synthesis, biological evaluation, QSAR and molecular dynamics simulation studies of potential fibroblast growth factor receptor 1 inhibitors for the treatment of gastric cancer

Accumulating evidence suggests that fibroblast growth factor receptor 1 (FGFR1) is an attractive target in gastric cancer therapy. Based on our previous discovery of two non-ATP competitive FGFR1 inhibitors, A114 and A117, we designed and screened a series of compounds with the framework of bisaryl-1,4-dien-3-one. Among them, D12 and D15 exhibited the most potent FGFR1 inhibitory activity, which was ATP-independent. Furthermore, a quantitative structure-activity relationship analysis of 41 analogs demonstrated that the specific structural substitutions alter their bioactivities. Molecular docking and dynamics simulation analysis indicated the hydrophobic interaction at the FGFR1-D12/D15 interaction was dominant. Evaluation for anti-gastric cancer efficacy of D12 and D15 indicated effective inhibition of cell proliferation, apoptosis induction and cell cycle arrest. Thus, these two FGFR1 inhibitors have therapeutic potential in the treatment of gastric cancer, and this study provides will contribute to the rational design of novel non-ATP competitive FGFR1 inhibitors.

Synthesis and biological evaluation of unsymmetrical curcumin analogues as tyrosinase inhibitors

Synthesis and biological evaluation of unsymmetrical curcumin analogues (UCAs) have been achieved. Tyrosinase inhibitory activities were found for most of the prepared synthetic UCAs. Among them, compounds containing 4-hydroxyl-substituted phenolic rings with C-2/C-4- or C-3/C-4-dihydroxyl- substituted diphenolic rings were more active (IC50 = 1.74~16.74 μM) than 4-butylresorcinol and kojic acid, which suggested that the 4-hydroxyl groups in UCAs play a crucial role in tyrosinase inhibitory activities. The inhibition kinetics analyzed by Lineweaver-Burk plots revealed compounds 3c and 3i containing catecholic rings were mixed-competitive inhibitors, whereas compounds 3d and 3j containing resorcinolic rings were competitive inhibitors. The preliminary evaluation results of acute toxicity showed the representative 3d and 3j were non-toxic in mice dosed at 1,200 mg/kg. This research suggests that, with the advantage of being readily prepared small molecules, polyphenolic UCAs have the potential to develop into pharmacological inhibitors of tyrosinase.

2-METHYLENE-5-SUBSTITUTED-METHYLENECYCLOPENTANONE DERIVATIVES AND USE THEREOF

The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.

2-METHYLENE-5-SUBSTITUTED METHYLENE CYCLOPENTANONE DERIVATIVES AND USE THEREOF

The invention relates to 2-methylene-5-substituted-methylenecyclopentanone derivatives of formula I, and the use thereof. The derivatives of formula I as active components are useful for preparing a medicine for the treatment and/or prevention of cancer diseases such as breast cancer, lung cancer, colon cancer, rectal cancer, stomach cancer, prostate cancer, bladder cancer, uterus cancer, pancreatic cancer and ovary cancer. The active compounds of the invention may be used as an anticancer drug alone or used in combination with one or more other antitumor drugs. A combined therapy can be carried out by administrating each therapeutic component concurrently, subsequently or separately.

Synthesis of CIS- and trans- 2-arylmethylcycloalkylamines: Potential dopaminergic agents

This paper reports the synthesis and the study of a few new diastereomeric arylmethylcycloalkylamines, tested as potential dopamine receptor active agents. New procedures for the stereospecific synthesis of the arylmethylcycloalkylamines were successfully experimented. All the considered compounds did not show any appreciable dopamine receptor activity.